Catalent, Inc. (NYSE:CTLT) Shares Purchased by Slotnik Capital LLC

Slotnik Capital LLC increased its position in Catalent, Inc. (NYSE:CTLT) by 45.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 283,500 shares of the company’s stock after buying an additional 88,000 shares during the quarter. Catalent accounts for approximately 5.7% of Slotnik Capital LLC’s investment portfolio, making the stock its 9th largest position. Slotnik Capital LLC owned approximately 0.16% of Catalent worth $17,172,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of Catalent in the third quarter valued at approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after acquiring an additional 14,373 shares during the last quarter. Quest Partners LLC boosted its holdings in Catalent by 289.8% in the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock valued at $2,986,000 after acquiring an additional 36,652 shares during the last quarter. Swedbank AB bought a new position in shares of Catalent during the 1st quarter worth approximately $1,659,000. Finally, New York Life Investment Management LLC lifted its holdings in shares of Catalent by 67.9% in the 2nd quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock worth $16,751,000 after purchasing an additional 120,502 shares in the last quarter.

Catalent Trading Up 0.2 %

Catalent stock opened at $61.12 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The business’s fifty day simple moving average is $59.90 and its two-hundred day simple moving average is $58.47. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The company has a market capitalization of $11.09 billion, a price-to-earnings ratio of -27.04, a price-to-earnings-growth ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the firm posted ($0.10) earnings per share. The company’s revenue was up 4.2% compared to the same quarter last year. As a group, equities analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.